A recent phase 3b clinical trial has revealed promising results in the fight against recurrent Clostridioides difficile infection (rCDI). Specifically, the study showed that Rebyota Fecal Microbiota, live-jslm (RBL), administered through colonoscopy, is a safe and efficacious preventative measure for those susceptible to recurrent bouts of the infection. The trial serves as a benchmark for…